Share on StockTwits
 

Onconova Therapeutics (NASDAQ:ONTX) Director Michael B. Hoffman acquired 57,295 shares of the stock on the open market in a transaction that occurred on Monday, January 27th. The shares were purchased at an average cost of $11.92 per share, for a total transaction of $682,956.40. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Separately, analysts at Citigroup Inc. upgraded shares of Onconova Therapeutics from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday, October 29th. They now have a $27.00 price target on the stock, down previously from $30.00.

Shares of Onconova Therapeutics (NASDAQ:ONTX) traded down 0.42% on Monday, hitting $11.97. 162,927 shares of the company’s stock traded hands. Onconova Therapeutics has a 52-week low of $10.80 and a 52-week high of $31.13. The stock’s 50-day moving average is $12.87 and its 200-day moving average is $19.37. The company’s market cap is $256.3 million.

Onconova Therapeutics (NASDAQ:ONTX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.66) by $0.68. The company had revenue of $1.12 million for the quarter, compared to the consensus estimate of $1.07 million. On average, analysts predict that Onconova Therapeutics will post $-5.36 earnings per share for the current fiscal year.

Onconova Therapeutics, Inc (NASDAQ:ONTX) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.